FORCONI FRANCESCO | Elenco docenti

placeholder-icon272x331.png

Francesco

Forconi

Ricercatore universitario

Moia, R., Dondolin, R., De Propris, M.S., Talotta, D., Mouhssine, S., Perutelli, F., et al. (2023). Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. HEMATOLOGICAL ONCOLOGY, 41(3), 567-570 [10.1002/hon.3080]. - dettaglio
Andritsos, L.A., Anghelina, M., Neal, J., Blachly, J.S., Mathur, P., Lele, O., et al. (2022). Development of a distributed international patient data registry for hairy cell leukemia. LEUKEMIA & LYMPHOMA, 63(13), 3021-3031 [10.1080/10428194.2022.2109157]. - dettaglio
Ravandi, F., Kreitman, R.J., Tiacci, E., Andritsos, L., Banerji, V., Barrientos, J.C., et al. (2022). Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. BLOOD CANCER JOURNAL, 12(12) [10.1038/s41408-022-00760-z]. - dettaglio
Grever, M., Andritsos, L., Banerji, V., Barrientos, J.C., Bhat, S., Blachly, J.S., et al. (2021). Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. LEUKEMIA, 35(7), 1864-1872 [10.1038/s41375-021-01257-7]. - dettaglio
Blunt, M.D., Koehrer, S., Dobson, R.C., Larrayoz, M., Wilmore, S., Hayman, A., et al. (2017). The dual Syk/JAK inhibitor cerdulatinib antagonizes b-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. CLINICAL CANCER RESEARCH, 23(9), 2313-2324 [10.1158/1078-0432.CCR-16-1662]. - dettaglio